(Q43280735)

18 November 2017

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

18 November 2017

0 references

0 references

cost-effectiveness analysis

1 reference

Stephanie R Earnshaw

1

1 reference

18 November 2017

Jonathan Graham

2

1 reference

18 November 2017

MerriKay Oleen-Burkey

3

1 reference

18 November 2017

Jane Castelli-Haley

4

1 reference

18 November 2017

Kenneth Johnson

5

1 reference

18 November 2017

language of work or name

1 reference

1 January 2009

1 reference

Applied Health Economics and Health Policy

18 November 2017

1 reference

18 November 2017

7

1 reference

18 November 2017

91-108

1 reference

18 November 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256144

18 November 2017

0 references

cites work

Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Cost of multiple sclerosis by level of disability: a review of literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Cost of managing an episode of relapse in multiple sclerosis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

A comprehensive assessment of the cost of multiple sclerosis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Effect of relapses on development of residual deficit in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

Willingness to pay for a quality-adjusted life year: in search of a standard

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256144

21 January 2018

Identifiers

DOI

10.1007/BF03256144

1 reference

18 November 2017

1 reference